Form 8-K - Current report:
SEC Accession No. 0001193125-23-175501
Filing Date
2023-06-27
Accepted
2023-06-27 06:05:31
Documents
16
Period of Report
2023-06-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d462067d8k.htm   iXBRL 8-K 35080
2 EX-4.1 d462067dex41.htm EX-4.1 61077
3 EX-10.1 d462067dex101.htm EX-10.1 170049
4 EX-99.1 d462067dex991.htm EX-99.1 16785
8 GRAPHIC g462067dsp14.jpg GRAPHIC 9137
  Complete submission text file 0001193125-23-175501.txt   492216

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA oric-20230624.xsd EX-101.SCH 2859
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20230624_lab.xml EX-101.LAB 18737
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20230624_pre.xml EX-101.PRE 11713
10 EXTRACTED XBRL INSTANCE DOCUMENT d462067d8k_htm.xml XML 3480
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 231043918
SIC: 2834 Pharmaceutical Preparations